Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2021-10-26 Director's Dealing
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-10-26 English
FORM 4
Director's Dealing
2021-10-26 English
FORM 4
Director's Dealing
2021-10-26 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes the completion of a sale of 57.5 million shares of common stock, including details about the underwriting agreement and gross proceeds. This is an update on a financing activity, specifically a capital raise through a stock offering. The document includes a press release as an exhibit and legal opinions related to the offering. The length is under 5,000 characters and it is a standalone announcement of a financing event, not a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-10-25 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of 50,000,000 shares of common stock by ADMA Biologics, Inc. It includes detailed information about the offering price, underwriting discounts, use of proceeds, risk factors, and other offering-related disclosures. The document is a formal offering document used to raise capital through the issuance of new shares. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, earnings release, or any other category. It is a detailed financing prospectus supplement, not merely an announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2021-10-21 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 21, 2021, reporting the pricing of a public offering of common stock by ADMA Biologics, Inc. It details the terms of the underwriting agreement, the number of shares offered, the price per share, and the expected closing date. The document also references a press release announcing the offering pricing. This type of filing is an update on the company's capital raising activities and financing transactions. It is not a full financial report, earnings release, or management discussion, but rather a current report on a material definitive agreement related to financing. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2021-10-21 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.